Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology
暂无分享,去创建一个
[1] Michelle A. Anderson,et al. Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessment. , 2010, The Journal of molecular diagnostics : JMD.
[2] M. Lerner,et al. Biomarker Identification in Human Pancreatic Cancer Sera , 2008, Pancreas.
[3] G. Gonye,et al. HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients , 2010, Annals of surgery.
[4] Eithne Costello,et al. A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. , 2009, Journal of proteomics.
[5] Y. Gong,et al. Identification of pancreatic juice proteins as biomarkers of pancreatic cancer. , 2010, Oncology reports.
[6] Eithne Costello,et al. Pancreatic Cancer: Proteomic Approaches to a Challenging Disease , 2009, Pancreatology.
[7] M. Verma. Pancreatic Cancer Epidemiology , 2005, Technology in cancer research & treatment.
[8] R. Hruban,et al. PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma , 2007, Clinical Cancer Research.
[9] S. Maehara,et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. , 2007, International journal of oncology.
[10] Quynh-Thu Le,et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. , 2010, Translational oncology.
[11] M. Verma. Proteomics and cancer epidemiology. , 2009, Methods in molecular biology.
[12] C. Verbeke,et al. Pathology of pancreatic tumours , 2010 .
[13] H. Brenner,et al. Stool testing for the early detection of pancreatic cancer: rationale and current evidence , 2008, Expert review of molecular diagnostics.
[14] D. Albanes,et al. Serum pepsinogen level, atrophic gastritis and the risk of incident pancreatic cancer--a prospective cohort study. , 2009, Cancer epidemiology.
[15] C. Iacobuzio-Donahue,et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer , 2010, British Journal of Cancer.
[16] G. V. Vande Woude,et al. Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.
[17] Debra T Silverman,et al. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[18] K. Lance,et al. Utility of cells exfoliated onto the esophagoscope as an aid in the diagnosis of esophageal carcinoma , 2005, The American Journal of Digestive Diseases.
[19] M. Verma. Biomarkers for Risk Assessment in Molecular Epidemiology of Cancer , 2004, Technology in cancer research & treatment.
[20] W. Greenhalf,et al. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer , 2010, British Journal of Cancer.
[21] R. Aebersold,et al. Proteomics studies of pancreatic cancer , 2007, Proteomics. Clinical applications.
[22] R. Zeillinger,et al. New and potential clinical applications of KRAS as a cancer biomarker. , 2010, Expert opinion on medical diagnostics.
[23] K. Sugano. [Molecular diagnosis of pancreatic cancer]. , 1997, Nihon Geka Gakkai zasshi.
[24] M. Verma,et al. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. , 2006, Critical reviews in oncology/hematology.
[25] D. Seminara,et al. Genetic and Epigenetic Biomarkers in Cancer , 2012, Molecular Diagnosis & Therapy.
[26] G. Hostetter,et al. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. , 2010, Biochemical pharmacology.
[27] Gilbert S. Omenn,et al. Alternative Splice Variants, a New Class of Protein Cancer Biomarker Candidates: Findings in Pancreatic Cancer and Breast Cancer with Systems Biology Implications , 2010, Disease markers.
[28] L. Miller,et al. A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma. , 2007, Gastroenterology.
[29] Y. Gong,et al. Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis , 2011, Digestive Diseases and Sciences.
[30] B. Nelson,et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia , 2010, Molecular Cancer.
[31] C. Logsdon,et al. Progress on molecular markers of pancreatic cancer , 2007, Current opinion in gastroenterology.
[32] C. Hajdu,et al. Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. , 2010, Anticancer research.
[33] Yong-Tae Kim,et al. Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer , 2010, PloS one.
[34] R Margreiter,et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer , 2008, British Journal of Cancer.
[35] H. Friess,et al. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. , 2008, European journal of cancer.
[36] H. Banerjee,et al. Epigenetic mechanisms in cancer. , 2009, Biomarkers in medicine.
[37] Yusuke Nakamura,et al. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma , 2009, Journal of Gastroenterology.
[38] Jeong-A Lim,et al. α-Syntrophin Modulates Myogenin Expression in Differentiating Myoblasts , 2010, PloS one.
[39] J. Ajani,et al. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. , 2010, Biomarkers in medicine.
[40] R. Andersson,et al. Diabetes Mellitus in Pancreatic Cancer and the Need for Diagnosis of Asymptomatic Disease , 2010, Pancreatology.
[41] David Elashoff,et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. , 2010, Gastroenterology.
[42] D. Albanes,et al. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. , 2008, American journal of epidemiology.
[43] B. Sitek,et al. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. , 2009, Journal of proteome research.
[44] M. Reni. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? , 2010, World journal of gastroenterology.
[45] S. Teutsch,et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.